186 related articles for article (PubMed ID: 31244659)
1. Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient.
Bühler T; Medinger M; Bouitbir J; Krähenbühl S; Leuppi-Taegtmeyer A
Front Pharmacol; 2019; 10():645. PubMed ID: 31244659
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents.
Haegler P; Joerin L; Krähenbühl S; Bouitbir J
Toxicol Sci; 2017 May; 157(1):183-195. PubMed ID: 28329820
[TBL] [Abstract][Full Text] [Related]
3. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
Lo Re V; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Haynes K; Roy JA; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA
Am J Med; 2016 Mar; 129(3):283-91.e5. PubMed ID: 26597673
[TBL] [Abstract][Full Text] [Related]
4. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis.
Martínez-Casanova J; Carballo N; Luque S; Sorli L; Grau S
Infect Drug Resist; 2018; 11():317-321. PubMed ID: 29551905
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation.
Oarbeascoa G; Dorado N; Bailén R; Serrano D; Balsalobre P; Pradillo V; Guinea J; Padilla B; Sancho M; Machado M; Buño I; Anguita J; Diez-Martin JL; Kwon M
Chemotherapy; 2019; 64(2):57-61. PubMed ID: 31484176
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
Heinz WJ; Egerer G; Lellek H; Boehme A; Greiner J
Mycoses; 2013 May; 56(3):304-10. PubMed ID: 23170837
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report.
Gu L; Ai T; Pang L; Xu D; Wang H
Infect Drug Resist; 2023; 16():5405-5411. PubMed ID: 37614681
[TBL] [Abstract][Full Text] [Related]
9. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
Müller C; Gehlen D; Blaich C; Prozeller D; Liss B; Streichert T; Wiesen MHJ
Ther Drug Monit; 2017 Oct; 39(5):505-513. PubMed ID: 28742650
[TBL] [Abstract][Full Text] [Related]
10. Clinical hepatotoxicity associated with antifungal agents.
Kyriakidis I; Tragiannidis A; Munchen S; Groll AH
Expert Opin Drug Saf; 2017 Feb; 16(2):149-165. PubMed ID: 27927037
[TBL] [Abstract][Full Text] [Related]
11. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
14. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database.
O'Flynn R; Zhou YP; Waskin H; Leong R; Straus W
Expert Opin Drug Saf; 2022 Aug; 21(8):1113-1120. PubMed ID: 35232318
[TBL] [Abstract][Full Text] [Related]
15. Graded isavuconazole introduction in a patient with voriconazole allergy.
Morales MK; Harris C; Shoham S
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28851131
[TBL] [Abstract][Full Text] [Related]
16. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes.
Luo X; Li T; Yu Z; Xue X; Zhao H; Li N; Ma L; Yang C; Huang L; Feng W
Xenobiotica; 2019 Jul; 49(7):753-761. PubMed ID: 29770723
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
19. Lack of hepato- and nephrotoxicity induced by antifungal drug voriconazole in laboratory rats.
Somchit N; Chung JH; Yaacob A; Ahmad Z; Zakaria ZA; Kadir AA
Drug Chem Toxicol; 2012 Jul; 35(3):304-9. PubMed ID: 22288423
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
